骨整合
骨保护素
兰克尔
骨质疏松症
材料科学
药物输送
双膦酸盐
破骨细胞
生物医学工程
生物相容性
骨重建
激活剂(遗传学)
药理学
牙科
癌症研究
医学
内科学
纳米技术
受体
植入
外科
冶金
作者
Yutao Cui,Zhonghan Wang,Zuhao Li,Jianhua Xuan,Baoming Yuan,Yu Sun,Chuangang Peng,Yangming Leng,Minghan Dou,Jincheng Wang,He Li,Dankai Wu
标识
DOI:10.1016/j.matdes.2021.109753
摘要
Osteoporosis leads to various complications, such as prosthesis loosening and periprosthetic fracture, after joint replacement. This is mainly due to the impaired osteogenesis and excessive osteoclastic activity in osteoporotic microenvironment, which leads to insufficient osseointegration between prostheses and host bone. In this study, a functional drug-releasing inorganic–organic bioactive interface was constructed, comprising inorganic three-dimensional (3D) printed porous titanium alloy interface and organic poloxamer 407 temperature-sensitive hydrogel loaded with a novel anti-osteoporosis drug (technetium methylenediphosphonate, 99Tc-MDP). The inorganic–organic bioactive interface showed good biocompatibility and exhibited a sustained release profile. This performance enhanced osteogenic differentiation, inhibited the expression of osteoclast-related genes and inhibited the osteoclastogenesis, as compared with traditional bisphosphonates (alendronate) in vitro. When implanted into the distal femoral defect using an osteoporotic rabbit model, the 99Tc-MDP-loaded bioactive interface exhibited the most stable osseointegration with native bone. Furthermore, the drug delivery system inhibited osteoclastic activity via regulation of the osteoprotegerin/receptor activator of NF-κB ligand (OPG/RANKL) signaling pathway, which significantly ameliorated the osteoporosis status to effectively prevent continuous bone destruction around the interface. This study has clinical significance, as it demonstrates that the 99Tc-MDP modified inorganic–organic interface serve as a novel artificial prosthetic interface for patients with poor osteogenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI